Kisunla

Master Formulation Record

The TRAILBLAZER-ALZ 2 study (NCT04437511) demonstrated significant clinical benefits of donanemab-azbt in early symptomatic Alzheimer disease (AD). Here are the key findings:Efficacy OutcomesCognitive & Functional....

Donanemab-azbt (Kisunla) demonstrates distinct advantages and trade-offs compared to other Alzheimer's treatments, particularly monoclonal antibody therapies like lecanemab and aducanumab. Here's a structured comparison:Mechanism of....

Drug Information